New York State Common Retirement Fund Sells 50,333 Shares of Hologic, Inc. (NASDAQ:HOLX)

New York State Common Retirement Fund trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 7.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 583,281 shares of the medical equipment provider’s stock after selling 50,333 shares during the quarter. New York State Common Retirement Fund owned approximately 0.22% of Hologic worth $30,453,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Hologic by 15.4% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 54,068 shares of the medical equipment provider’s stock valued at $2,806,000 after acquiring an additional 7,233 shares during the last quarter. US Bancorp DE boosted its position in shares of Hologic by 57.2% during the 4th quarter. US Bancorp DE now owns 17,278 shares of the medical equipment provider’s stock valued at $902,000 after acquiring an additional 6,286 shares during the last quarter. Mesirow Financial Investment Management Equity Management boosted its position in shares of Hologic by 2.0% during the 4th quarter. Mesirow Financial Investment Management Equity Management now owns 36,185 shares of the medical equipment provider’s stock valued at $1,889,000 after acquiring an additional 725 shares during the last quarter. Advisory Services Network LLC boosted its position in shares of Hologic by 36.7% during the 4th quarter. Advisory Services Network LLC now owns 2,773 shares of the medical equipment provider’s stock valued at $145,000 after acquiring an additional 745 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Hologic during the 4th quarter valued at $229,000. Institutional investors and hedge funds own 95.93% of the company’s stock.

NASDAQ:HOLX opened at $53.02 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.20 and a current ratio of 1.57. The stock’s fifty day moving average is $53.27 and its 200 day moving average is $50.64. Hologic, Inc. has a fifty-two week low of $42.61 and a fifty-two week high of $55.25. The firm has a market capitalization of $13.81 billion, a PE ratio of 57.63, a PEG ratio of 2.31 and a beta of 0.85.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, January 29th. The medical equipment provider reported $0.61 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.61. Hologic had a return on equity of 30.47% and a net margin of 7.30%. The business had revenue of $850.50 million for the quarter, compared to analyst estimates of $849.40 million. During the same quarter last year, the firm posted $0.58 earnings per share. The business’s revenue was up 2.4% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 2.65 EPS for the current year.

In other Hologic news, insider Benjamin Jordan Cohn sold 4,400 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $50.09, for a total value of $220,396.00. Following the sale, the insider now owns 23,063 shares in the company, valued at $1,155,225.67. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel John M. Griffin sold 19,624 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $52.86, for a total value of $1,037,324.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,057 shares of company stock worth $2,946,575. Insiders own 1.00% of the company’s stock.

Several analysts recently weighed in on HOLX shares. Leerink Swann restated a “hold” rating and set a $50.00 price target on shares of Hologic in a report on Wednesday, November 20th. TheStreet upgraded Hologic from a “c” rating to a “b+” rating in a report on Wednesday, January 29th. BidaskClub lowered Hologic from a “buy” rating to a “hold” rating in a report on Thursday, February 6th. Morgan Stanley lowered Hologic from an “equal weight” rating to an “underweight” rating in a report on Thursday, January 2nd. Finally, William Blair restated a “buy” rating on shares of Hologic in a report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $55.93.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.